e-Drug3D

1728

cas 491833-29-5

CLASS

METABOLISM
A GLUCOSYLCERAMIDE SYNTHASE INHIBITOR
LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1
RESEMBLES THE CERAMIDE SUBSTRATE

ROUTE (list)

ORAL

PK parameters

Tmax 3 HOUR
VD 835 LITER
Cl 88 LITER / HOUR
PPB 79.5 PERCENT
t1/2 8.9 HOUR

MW 404.54
NB_atoms 29
XLogP 3.43
PSA 61.606
NB_HD 2
NB_HA 6
fsp3 0.70
Lipinski(0=no;1=yes) 1

FDA
NDA 205494 (label) INN (ELIGLUSTAT TARTRATE) CERDELGA (GENZYME CORP) APPROVAL= AP YEAR= 2014 NEWMOLECULARENTITY
NDA 212463 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (AIZANT) APPROVAL= AP YEAR= 2021
NDA 212474 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (TEVA PHARMS USA INC) APPROVAL= AP YEAR= 2021 DISCONTINUED
NDA 212449 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (DR REDDYS) APPROVAL= AP YEAR= 2022 DISCONTINUED
NDA 212420 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (UPSHER SMITH LABS) APPROVAL= AP YEAR= 2023
NDA 212369 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (CIPLA) APPROVAL= AP YEAR= 2024
NDA 212425 (pdf not found) INN (ELIGLUSTAT TARTRATE) ELIGLUSTAT TARTRATE (APOTEX) APPROVAL= AP YEAR= 2024 DISCONTINUED